{{위키데이터 속성 추적}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 470624518
| IUPAC_name = (4b''S'',8a''R'',9''S'')-3-Methoxy-11-methyl-6,7,8,8a,9,10-hexahydro-5''H''-9,4b-(epiminoethano)phenanthrene
| image = Dextromethorphan.svg
| image2 = Dextromethorphan-from-xtal-3D-balls-A.png

<!--Clinical data-->
| tradename = Robitussin, Delsym, DM, DexAlone, Duract, others
| Drugs.com = {{drugs.com|monograph|dextromethorphan-hydrochloride}}
| MedlinePlus = a682492
| pregnancy_AU = A
| pregnancy_US = C
| legal_UK = P
| legal_AU = S2
| legal_US = OTC
| legal_CA = OTC
| legal_status =
| routes_of_administration = [[:en:Oral administration|By mouth]]
| dependency_liability = Low

<!--Pharmacokinetic data-->
| bioavailability = 11%<ref name="pmid15500572">{{저널 인용|doi=10.1111/j.1365-2885.2004.00608.x |pmid=15500572 |title=Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogs |journal=Journal of Veterinary Pharmacology and Therapeutics |volume=27 |issue=5 |pages=337–41 |year=2004 |last1=Kukanich |first1=B. |last2=Papich |first2=M. G.}}</ref>
| metabolism = Hepatic (liver) enzymes: major [[:en:CYP2D6]], minor [[:en:CYP3A4]], and minor [[:en:CYP3A5]]
| elimination_half-life = 2–4 hours ([[약물유전체학]]s); 24 hours ([[약물유전체학]]s)<ref name = MSR>{{웹 인용|title=Balminil DM, Benylin DM (dextromethorphan) dosing, indications, interactions, adverse effects, and more|work=Medscape Reference|publisher=WebMD|accessdate=15 April 2014|url=http://reference.medscape.com/drug/balminil-dm-benylin-dm-dextromethorphan-343401#showall}}</ref>
| excretion = [[콩팥|Renal]]

<!--Identifiers-->
| IUPHAR_ligand = 6953
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 125-71-3
| ATC_prefix = R05
| ATC_suffix = DA09
| PubChem = 15978238
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00514
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 13109865
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7355X3ROTS
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D03742
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 4470
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 52440

<!--Chemical data-->
| C=18 | H=25 | N=1 | O=1
| molecular_weight = 271.40 g/mol
| SMILES = CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc4c3cc(cc4)OC
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MKXZASYAUGDDCJ-NJAFHUGGSA-N
| melting_point = 111
}}

'''덱스트로메토르판'''({{lang|en|dextromethorphan}}, '''DXM''' 또는 '''DM''' 또는 D-Methorphan)은 [[일반의약품|처방전 없이 구매가 가능한]] [[감기]], [[기침]]용 약물이자 [[기침 억제제]]로서 대부분 사용되는 약물이다. [[시럽]], 알약, 스프레이, [[목구멍용 트로키제]] 형태로 판매된다.

[[진정제]], [[해리성]], [[각성제]] 속성(적은 량 복용 시)을 갖춘 [[모르피난]]계 약물에 속한다. 순수 형태에서 덱스트로메토르판은 흰 가루 형태이다.<ref name="urlReference Tables: Description and Solubility - D">{{웹 인용|url=http://www.pharmacopeia.cn/v29240/usp29nf24s0_alpha-2-13.html|title=Reference Tables: Description and Solubility - D|last=|first=|date=|work=|publisher=|pages=|archive-url=https://web.archive.org/web/20170704164745/http://www.pharmacopeia.cn/v29240/usp29nf24s0_alpha-2-13.html|archive-date=2017-07-04|url-status=dead|accessdate=2011-05-06|vauthors=}}</ref>

DXM은 또한 [[덱스트로메토르판의 레크리에이션 이용|레크리에이션]] 목적으로도 사용된다. 승인된 양 이상으로 과다 복용할 경우 덱스트로메토르판은 해리성 [[마취제]]의 역할을 한다. 여러 [[작용기서]]가 있으며 여기에는 비선택적 [[세로토닌 재흡수 억제제]]<ref name="Schwartz, Pizon, Brooks 2008">{{저널 인용|doi=10.1080/15563650701668625 |pmid=19238739 |title=Dextromethorphan-induced serotonin syndrome |journal=Clinical Toxicology |volume=46 |issue=8 |pages=771–3 |year=2008 |last1=Schwartz |first1=Anna R. |last2=Pizon |first2=Anthony F. |last3=Brooks |first3=Daniel E. }}</ref>, [[시그마-1 수용체|시그마-1]] [[세포 표면 수용체|수용체]] 작용제로서의 동작이 포함된다.<ref name="pmid17386960">{{저널 인용|doi=10.1016/j.neuint.2007.01.008 |pmid=17386960 |title=Dextromethorphan attenuates trimethyltin-induced neurotoxicity via σ1 receptor activation in rats |journal=Neurochemistry International |volume=50 |issue=6 |pages=791–9 |year=2007 |last1=Shin |first1=E |last2=Nah |first2=S |last3=Chae |first3=J |last4=Bing |first4=G |last5=Shin |first5=S |last6=Yen |first6=T |last7=Baek |first7=I |last8=Kim |first8=W |last9=Maurice |first9=T |last10=Nabeshima |first10=T |last11=Kim |first11=H. C. }}</ref><ref name="pmid15723099">{{저널 인용|doi=10.1038/sj.bjp.0705998 |pmid=15723099 |pmc=1576070 |title=The dextromethorphan analog dimemorfan attenuates kainate-induced seizuresvia σ1receptor activation: Comparison with the effects of dextromethorphan |journal=British Journal of Pharmacology |volume=144 |issue=7 |pages=908–18 |year=2005 |last1=Shin |first1=Eun-Joo |last2=Nah |first2=Seung-Yeol |last3=Kim |first3=Won-Ki |last4=Ko |first4=Kwang Ho |last5=Jhoo |first5=Wang-Kee |last6=Lim |first6=Yong-Kwang |last7=Cha |first7=Joo Young |last8=Chen |first8=Chieh-Fu |last9=Kim |first9=Hyoung-Chun}}</ref> DXM과 그 주요 [[대사물질]], [[덱스트로판]] 또한 많은 양을 복용할 경우 [[NMDA 수용체 길항제]]의 역할을 하며 이는 [[케타민]], [[펜시클리딘]]과 같은 다른 해리성 마취제가 만들어내는 해리성 상태와 비슷한 효과를 내지만 이와는 구별된다.

1949년 특허를 받았으며 1953년 의학용으로 승인되었다.<ref name=Fis2006>{{서적 인용|last1=Fischer |first1=Jnos |last2=Ganellin |first2=C. Robin |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=527 |url=https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA527 |language=en}}</ref>

== 예 ==
Dextromethorphan Hydrobromide Hydrate은 결합형태의 예이다.<ref>(Dextromethorphan (hydrobromide hydrate)
Item № 13950
CAS № 6700-34-1
Purity ≥98%)https://www.caymanchem.com/product/13950</ref>

== 같이 보기 ==
* [[구아이페네신]]
* [[아세트아미노펜]]

== 각주 ==
{{각주}}

== 외부 링크 ==
{{위키공용분류}}
* [http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Dextromethorphan U.S. National Library of Medicine: Drug Information Portal - Dextromethorphan]
* [https://web.archive.org/web/20101125083631/http://treatmentsclerosis.com/index.php/drugs-meds/nuedexta Nuedexta (dextromethorphan hydrobromide and quinidine sulfate): Prescribing Information (Original Approval Date FDA: October 29, 2010)]

{{전거 통제}}

[[분류:기침약]]
[[분류:페놀 에터]]
[[분류:전구약물]]
[[분류:NMDA 수용체 대항제]]
[[분류:니코틴 대항제]]
[[분류:뮤 오피오이드 수용체 작용제]]
[[분류:세로토닌-노르에피네프린 재흡수 억제제]]
[[분류:모르피난]]
[[분류:벤조모르판]]